COGNITION THERAPEUTICS INC
Cognition Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics for age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, also known as CT1812, an orally delivered molecule designed to prevent pathogenic protein oligomers from binding to neuronal synapses. Cognition is evaluating zervimesine in Alzheimer’s disease and has completed a Phase 2 study in dementia with Lewy bodies. It also conducted a Phase 2 study for geographic atrophy secondary to dry age-related macular degeneration, which concluded in January 2025. Cognition’s activities center on developing its own therapeutic candidate; it retains all worldwide rights to zervimesine. Its clinical trials have been funded primarily by grants, including awards from the National Institute on Aging. Cognition is headquartered in Purchase, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CGTX in the last 30 days.
See all $CGTX insider activity →Cognition Therapeutics (CGTX) reported Q3 earnings, highlighting progress in its zervimesine drug trials for dementia with Lewy bodies (DLB) and Alzheimer's. The drug showed an 89% reduction in psychosis symptom progression in a Phase II study. The company expects cash to last into Q4 2027. Cognition also discussed cost reductions for upcoming trials and reported a net loss of $4.1 million for Q3.
Cognition Therapeutics (CGTX) received a notice from Nasdaq on November 3, 2026, for failing to maintain a minimum closing bid price of $1.00 for 30 consecutive days. The company has until May 3, 2027, to comply with the listing rule. Its stock continues to trade on the Nasdaq Capital Market without immediate impact.
COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update - Management conference call at 8:30 a.m. ET today - Purchase, NY – November 5, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company devel
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning CGTX (COGNITION THERAPEUTICS INC). Coverage has skewed bullish: 6 bullish, 2 neutral, and 1 bearish.
Recent CGTX coverage spans earnings, regulation and technology.
Positive Phase II data and sufficient cash may support upside, but net loss and limited funding constrain near-term risk.
The compliance notice creates downside risk as the stock remains below the $1 threshold.
The quarterly loss and modest cash runway may pressure the stock, while progress on the Phase 3 DLB trial could provide upside if data are positive.
Regulatory alignment reduces uncertainty for the upcoming pivotal trial, supporting near‑term share upside.
The FDA alignment removes a major regulatory uncertainty, likely supporting the stock price.
AlphAI scores every news story that mentions CGTX with an AI model for sentiment and relevance, and aggregates insider trades from COGNITION THERAPEUTICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cognition Therapeutics (CGTX) reported Q3 earnings, highlighting progress in its zervimesine drug trials for dementia with Lewy bodies (DLB) and Alzheimer's. The drug showed an 89% reduction in psychosis symptom progression in a Phase II study. The company expects cash to last into Q4 2027. Cognition also discussed cost reductions for upcoming trials and reported a net loss of $4.1 million for Q3.
Cognition Therapeutics (CGTX) received a notice from Nasdaq on November 3, 2026, for failing to maintain a minimum closing bid price of $1.00 for 30 consecutive days. The company has until May 3, 2027, to comply with the listing rule. Its stock continues to trade on the Nasdaq Capital Market without immediate impact.
COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update - Management conference call at 8:30 a.m. ET today - Purchase, NY – November 5, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company devel
COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies PURCHASE, NY – October 22, 2026 – Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company deve
Cognition Therapeutics (NASDAQ: CGTX) has aligned with the FDA on a Phase 3 study for its drug zervimesine (CT1812) to treat dementia with Lewy bodies (DLB). The study will enroll patients with mild-to-moderate DLB, using neuropsychiatric inventory and daily function scales as endpoints. The company aims to address a disease with no approved treatments, affecting an estimated 1.4 million Americans.
H.C. Wainwright reiterated a Buy rating and $3.00 price target for Cognition Therapeutics (CGTX) after the company received a patent for a new form of its lead drug, zervimesine. The patent extends to 2045, with possible extensions. CGTX is down 13% in the past week, but analysts maintain a Strong Buy consensus with targets ranging from $3 to $4.
Cognition Therapeutics (CGTX) received a patent for a crystalline form of CT1812, expiring in 2045. The company plans to begin manufacturing in Q1 2027 for a DLB trial. The patent extends IP protection for CT1812 as the company advances toward a registrational program.
Cognition Therapeutics (CGTX) received a patent for a new form of its lead drug, zervimesine, expiring in 2045, with a potential 5-year extension upon FDA approval. The patent covers the drug's composition, production, and therapeutic methods. The company plans to begin manufacturing this form in Q1 2027 for clinical trials in dementia with Lewy bodies (DLB).
Taiho Pharmaceutical and Cullinan Therapeutics said their Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line advanced NSCLC with EGFR exon 20 insertion mutations met the primary endpoint at interim analysis. They reported statistically significant, clinically meaningful progression-free survival improvement versus chemotherapy alone, without disclosing figures. Zipalertinib is under FDA review for previously treated patients.
COGNITION THERAPEUTICS INC (CGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative
